Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade.
CONCLUSION: irPR features are consistent across tumor types and treatment settings. Standardized, pan-tumor immune-mediated pathologic response criteria (irPRC) are defined and associated specimen-handling considerations are described. Future, prospective studies are merited to validate irPRC in larger datasets and to associate pathologic features with long-term patient outcomes. PMID: 31672770 [PubMed - as supplied by publisher]
This study investigated the protein expression profile of STC1 in PCa and benign prostatic hyperplasia (BPH) samples and STC1 signalling during cell proliferation and cell death in vitro using cell lines. We found higher levels of STC1 in PCa when compared to BPH tissue and that STC1 inhibited forskolin stimulation of cAMP in PC-3 cells. A monoclonal antibody against STC1 was effective in reducing cell proliferation, in promoting cell cycle arrest, and in increasing apoptosis in the same cells. Since STC1 acts as a regulator of prostatic tissue signalling, we suggest that this protein is a novel candidate biomarker for p...
ConclusionLCH mostly occurs in children. In head and neck it affects principally the mastoid part of the temporal bone. Treatments include surgery, chemotherapy, and irradiation. Most patients enjoy good prognoses. LCH accompanied by TCS is rare and increases the difficulty of diagnosis; molecular data aid in TCS identification.
Publication date: Available online 6 December 2019Source: Trends in Pharmacological SciencesAuthor(s): Lorenzo GalluzziAlthough somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRASG12C inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers.
ConclusionABCB1 C3435T and ABCG2 C421A might represent a potential risk factor for breast cancer for Turkish women.
ConclusionThe findings suggest that chitosan, as a prime drug-delivery carrier, significantly alleviates the acute and sub-acute toxic effects of 6-MP.
ConclusionResults of this study demonstrated the potential of MWL oil in the development of natural anticancer therapeutic agents.Graphical abstract
Publication date: Available online 6 December 2019Source: International Journal of PharmaceuticsAuthor(s): Iftikhar Khan, Maria Apostolou, Ruba Bnyan, Chahinez Houacine, Abdelbary Elhissi, Sakib S YousafAbstractA simplistic approach was conducted to manufacture novel paclitaxel (PTX) loaded protransfersome tablet formulations for pulmonary drug delivery. Large surface area presented by pulmonary system offer better target using anti-cancer drug deposition for localized effect in the lungs. Protransfersomes are dry powder formulations, whereas transfersomes are liquid dispersions containing vesicles generated from protransf...
Conclusion: These results conclude that G.A has the potential to reduce metastatic melanoma through its anti-proliferative and anti-metastatic effects.Graphical abstract
Publication date: Available online 22 October 2019Source: Seminars in Cancer BiologyAuthor(s): Tamara T. Lah, Metka Novak, Barbara BreznikAbstractBrain, the major organ of the central nervous system controls and processes most of body activities. Therefore, the most aggressive brain tumor – glioblastoma and metastases from other organs to the brain are lethal leaving the patients with very short time of survival. The brain tissue landscape is very different from any other tissues and the specific microenvironment, comprising stem cells niches and blood-brain barrier, significantly influences the low rate of glioblast...
Publication date: March 2020Source: Journal of Cancer Policy, Volume 23Author(s): Brandon Maser, Lisa M. Force, Paola Friedrich, Federico Antillon, Ramandeep S. Arora, Cristian A. Herrera, Carlos Rodriguez-Galindo, Rifat Atun, Avram DenburgAbstractTo help understand how health systems and sociopolitical contexts intersect with and impact the performance of childhood cancer care in low- and middle-income countries (LMICs), we have developed a systems-level framework for analyzing the performance of LMIC childhood cancer programs within their health system contexts: The Paediatric Oncology System Integration Tool (POSIT). PO...
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Gastroschisis Repair | Head and Neck Cancer | Immunotherapy | Kidney Cancer | Melanoma | Merkel Cell Carcinoma | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer | Squamous Cell Carcinoma | Study